Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) Short Interest Update

Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) saw a significant growth in short interest in February. As of February 15th, there was short interest totalling 641,700 shares, a growth of 95.8% from the January 31st total of 327,700 shares. Based on an average daily trading volume, of 0 shares, the short-interest ratio is currently ∞ days.

Hansa Biopharma AB (publ) Stock Performance

HNSBF remained flat at $3.00 on Friday. Hansa Biopharma AB has a twelve month low of $2.83 and a twelve month high of $3.65. The business has a fifty day moving average price of $2.98 and a 200-day moving average price of $3.09.

About Hansa Biopharma AB (publ)

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test.